Evidence map›Paper›PMID 37696999›Full record

ArticleAmino acids2023

PDZK1 improves ventricular remodeling in hypertensive rats by regulating the stability of the Mas receptor.

Jinyu Chi, Wanlin Li, Yang Xu, Xiuzhi Li, Xiaohui Zhang, Zhiyu Shi, Chunnan Liu, Wenxiu Liu, Meng Zhao, Yan Meng and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Amino acids, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Jinyu ChiFirst Affiliated Hospital of Harbin Medical University, Harbin, China.
Wanlin LiFirst Affiliated Hospital of Harbin Medical University, Harbin, China.
Yang XuFirst Affiliated Hospital of Harbin Medical University, Harbin, China.
Xiuzhi LiFirst Affiliated Hospital of Harbin Medical University, Harbin, China.
Xiaohui ZhangFirst Affiliated Hospital of Harbin Medical University, Harbin, China.
Zhiyu ShiFirst Affiliated Hospital of Harbin Medical University, Harbin, China.
Chunnan LiuFirst Affiliated Hospital of Harbin Medical University, Harbin, China.
Wenxiu LiuFirst Affiliated Hospital of Harbin Medical University, Harbin, China.
Meng ZhaoFirst Affiliated Hospital of Harbin Medical University, Harbin, China.
Yan MengFirst Affiliated Hospital of Harbin Medical University, Harbin, China.
Dechao ZhaoFirst Affiliated Hospital of Harbin Medical University, Harbin, China. zhaodechao2020@163.com.
First Affiliated Hospital of Harbin Medical University · CNHarbin Medical University · CN

Funding

National Natural Science Foundation of China 81570340the National Science Foundation for Distinguished Young Scholars of China 81800352the Postdoctoral Scientific Research Developmental Fund of Heilongjiang Province LBH-Q18093Young Medical Talents Funding Project of the First Affiliated Hospital of Harbin Medical University 2021J16
6 · The paper itself

Abstract

Ventricular remodeling is one of the main causes of mortality from heart failure due to hypertension. Exploring its mechanism and finding therapeutic targets have become urgent scientific problems to be solved. A number of studies have shown that Mas, as an Ang-(1-7) specific receptor, was significantly reduced in myocardial tissue of rats undergoing hypertensive ventricular remodeling. It has been reported that Mas receptor levels are significantly downregulated in myocardium undergoing ventricular remodeling, but studies focused on intracellular and post-translational modifications of Mas are lacking. The results of this research are as follows: (1) PDZK1 interacts with the carboxyl terminus of Mas through its PDZ1 domain; (2) the expression of PDZK1 and Mas is decreased in rats undergoing hypertensive ventricular remodeling, and PDZK1 upregulation can ameliorate hypertensive myocardial fibrosis and myocardial hypertrophy; (3) PDZK1 enhances the stability of Mas protein through the proteasome pathway, and the proteasome inhibitor MG132 promotes hypertensive ventricular remodeling. PDZK1 improves ventricular remodeling in hypertensive rats by regulating Mas receptor stability. This study provides a scientific basis for the prevention and treatment of ventricular remodeling.

Indexed as

Heart FailureHypertensionAnimalsCardiomegalyCytoskeletal ProteinsFibrosisMyocardiumRatsVentricular RemodelingCytoskeletal ProteinsPdzk1 protein, ratMas receptorPDZK1Protein interactionUbiquitin proteasome pathwayVentricular remodeling

Identifiers

PMID37696999
OpenAlexW4386609392

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.